About this Research Topic
The myeloproliferative neoplasms (MPNs) are a group of clonal stem cell diseases with heterogeneous clinical features and laboratory characteristics. The MPNs field is rapidly evolving due to the discovery of driver mutations including JAK2, MPL, and CALR mutations. The advance in the molecular pathogenesis of MPNs has a direct impact on the innovation of new treatments such as JAK inhibitors. However, the management of patients with MPNs is still challenging especially in the setting of disease transformation or after the development of resistance to JAK inhibitors. Therefore, novel strategies for the study and management of MPNs are urgently needed.
The scope and aim of this Research Topic will focus on novel strategies for the management of MPNs. All novel findings regarding the mutational profiles, molecular pathogenesis, animal models, treatment and prognosis on MPNs will be considered for this collection. We encourage submissions addressing questions such as:
1) The molecular pathogenesis of disease transformation in MPNs
2) Novel animal models of MPNs
3) The role of microRNA in the pathogenesis of MPNs
4) Treatment after resistance to JAK inhibitors in MPNs
5) Novel treatment approaches to MPNs
6) Genomics and classification based on last WHO classification and diagnostic criteria for MPNs
7) Role of allogeneic hematopoietic stem cell transplant
8) Real-world data on practice patterns and outcomes
We welcome submissions of the Original Research articles as well as Reviews or Mini-Reviews describing the current state of knowledge regarding the above-mentioned topics.
Keywords: Myeloproliferative neoplasms, treatment, JAK inhibitor, pathogenesis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.